logomg.png
Open an Account
Open an Account
  • Ripple-loading

  • SENSEX

    {{sensexData[0].price}} (+{{sensexData[0].change}}%)

  • SENSEX

    {{sensexData[0].price}} ({{sensexData[0].change}}%)

  • Ripple-loading

  • NIFTY 50

    {{niftyData[0].open_price}} (+{{niftyData[0].change}}%)

  • NIFTY 50

    {{niftyData[0].open_price}} ({{niftyData[0].change}}%)

  • Ripple-loading

  • {{mcxData[2].symbol}}

    {{mcxData[2].price}} (+{{mcxData[2].PerChange}}%)

  • {{mcxData[2].symbol}}

    {{mcxData[2].price}} ({{mcxData[2].PerChange}}%)

  • {{mcxData[0].symbol}}

    {{mcxData[0].price}} (+{{mcxData[0].PerChange}}%)

  • {{mcxData[0].symbol}}

    {{mcxData[0].price}} ({{mcxData[0].PerChange}}%)

  • Ripple-loading

  • {{mcxData[1].symbol}}

    {{mcxData[1].price}} (+{{mcxData[1].PerChange}}%)

  • {{mcxData[1].symbol}}

    {{mcxData[1].price}} ({{mcxData[1].PerChange}}%)

  • Ripple-loading

  • {{mcxData[3].symbol}}

    {{mcxData[3].price}} (+{{mcxData[3].PerChange}}%)

  • {{mcxData[3].symbol}}

    {{mcxData[3].price}} ({{mcxData[3].PerChange}}%)

Back
Alembic Pharma Q1 PAT rises 12% YoY to ₹ 135 cr 
(15:48, 08 Aug 2024)
Revenue from operations grew 5.09% year on year (YoY) to ₹ 1,561.73 crore in the quarter ended 30 June 2024.

Profit before tax was at ₹ 157.03 crore in Q1 FY25, up 21.02% from ₹ 129.76 crore recorded in the corresponding quarter previous year.

EBIDTA grew 14% YoY to ₹ 239 crore while EBIDTA margin stood at 15.3% during the period under review.

On the segmental front, API revenue was ₹ 259 crore (down 15% YoY). In the Formulations business, India revenue was ₹ 572 crore (up 9% YoY), US revenue was ₹ 461 crore (up 18% YoY) and Ex-US revenue was ₹ 271 crore (up 2% YoY).

Shaunak Amin, MD of Alembic Pharmaceuticals said, 'India Branded Business continues to work on improving the execution ability both in quality & scale. The Specialty and Animal health segment witnessed robust growth.

The USFDA conducted an audit at our Formulation facility F1, without any observations, underscoring our dedication to compliance and quality. The US business grew by 18% during the quarter.'

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.

The scrip shed 0.11% to end at ₹ 1,218.65 on the BSE. The counter hit an all-time high of ₹ 1,285.60 in today's intraday session.

Powered by Capital Market - Live News

No Details of this news available
Mandatory Dematerialization for Transfer of Securities, w.e.f 5th December 2018. Refer to SEBI notification number SEBI/LAD-NRO/GN/2018/24 dated June 08,2018. Update/Link your Aadhaar Number with your Demat Account by Submitting a photocopy of Aadhaar card along with a request letter/Modification form. Prevent Unauthorised transactions in your account. Update your mobile numbers/email IDs with your stock brokers. Prevent unauthorized transactions in your trading account ->Update your mobile numbers/email IDs with your stock brokers. Receive information/alerts of your transactions directly from Exchange on your mobile/email at the end of the day.... Issued in the interest of investors.
Prevent Unauthorized Transactions in your demat account. Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day....... Issued in the interest of investors.
KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment.

Filing Complaints on SCORES - Easy & quick.
a. Register on SCORES portal,
b. Provide mandatory details for filing complaints on SCORES like name, PAN, address, mobile number, email ID.
c. Benefits:
   i. Effective communication
   ii. Speedy redressal of the grievances

Investor Awareness regarding the revised guidelines on margin collection

 

Dear Investor,

As you are aware, under the rapidly evolving dynamics of financial markets, it is crucial for investors to remain updated and well-informed about various aspects of investing in securities market. In this connection, please find a link to the BSE Investor Protection Fund website where you will find some useful educative material in the form of text and videos, so as to become an informed investor.

https://www.bseipf.com/investors_education.html

We believe that an educated investor is a protected investor !!!

 

Risk Disclosure on Derivatives

  • out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:
SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

MAGNUM EQUITY BROKING LTD.

SEBI Registration No.: INZ000172031 NSE Member ID: 06529 | BSE Clearing No.:126 | CDSL SEBI Registration No. IN-DP-CDSL-201-2003
DP ID: 12029700 | CIN: U67120MH1996PLC103441

Investor Grievances: grievances@magnum.co.in

Copyright © 2018-2019 Magnum Equity Broking Ltd. All rights reserved

Designed, Developed and Maintained by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)